Hera Biotech is a pioneering startup focused on revolutionizing the diagnosis and treatment of endometriosis, a painful and often debilitating condition affecting millions of women worldwide. The company is developing and commercializing MetriDx, the first non-surgical test for the definitive diagnosis and staging of endometriosis. This innovative approach aims to replace the current standard, which requires invasive laparoscopic surgery, making diagnosis safer, quicker, and more accessible.

Hera Biotech primarily serves healthcare providers, including gynecologists and general practitioners, who are on the front lines of diagnosing and treating women's health issues. By offering a non-invasive diagnostic tool, Hera Biotech aims to improve patient outcomes and reduce the economic burden associated with endometriosis, which is estimated to cost the U.S. healthcare system around $80 billion annually.

Operating in the women's health market, Hera Biotech's business model revolves around the commercialization of its proprietary diagnostic test, MetriDx. The company generates revenue by selling these diagnostic kits to healthcare providers and medical institutions. Additionally, Hera Biotech may explore partnerships with pharmaceutical companies and research institutions to further expand its market reach and application of its technology.

Hera Biotech's mission is to relentlessly seek to understand the root causes of diseases in women's health, thereby uncovering new ways of diagnosing and treating them. The company's collaborative culture is driven by a commitment to advancing the standard of care in women's health, making it a key player in this specialized medical field.

Keywords: Endometriosis, Non-surgical, Diagnosis, Women's Health, MetriDx, Healthcare Providers, Innovation, Medical Technology, Patient Outcomes, Economic Burden.